Floatz logo

Recombinant Human EGF-rP64K

Advanced Squamous Non-Small Cell Lung Carcinoma

Roswell Park Cancer InstitutePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

54 Active assets in the Advanced Squamous Non-Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BBB
Pembrolizumab
Shanghai Henlius Biotech
Phase 3BB
Serplulimab
Shanghai Henlius Biotech
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BB
Docetaxel
Shanghai Henlius Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Recombinant Human EGF-rP64K is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
lung cancerDormant
BB
Indicative ·
65 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →